The Xenetic Biosciences Inc (XBIO) Rating Increased to Hold at Zacks Investment Research

The Xenetic Biosciences Inc (XBIO) Rating Increased to Hold at Zacks Investment Research

According to Zacks, “Xenetic Biosciences Inc. is a biopharmaceutical company. It develops biologic drugs, oncology therapeutics and vaccinations. The Company’s proprietary drug technology platforms include PolyXen (R) for the development of next generation biologic drugs and OncoHist (R) for the development of oncology drugs focused on orphan indications. Xenetic Biosciences Inc. based in United States. “

Zacks Investment Research upgraded shares of Xenetic Biosciences Inc (NASDAQ:XBIO) from a sell rating to a hold rating in a research note released on Tuesday.

Xenetic Biosciences (XBIO) opened at 3.13 on Tuesday. The stock’s 50 day moving average price is $3.84 and its 200 day moving average price is $4.07. Xenetic Biosciences has a 1-year low of $2.35 and a 1-year high of $5.90. The company’s market cap is $27.28 million. Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Tuesday, May 16th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by $0.13. On average, equities analysts anticipate that Xenetic Biosciences will post ($0.89) earnings per share for the current fiscal year.

About Xenetic Biosciences Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:XBIO”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on Xenetic Biosciences (XBIO) For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment